Search

Background: Acral vitiligo is a significantly distressing condition and tends to be treatment-resistant. The occurrence of new lesions on acral areas further causes greater psychological trauma. Topical tacrolimus has been widely used in the management of vitiligo and its role in preventing flares in other dermatoses such as atopic dermatitis has been well documented., Objectives: To assess the role of topical tacrolimus as preventive therapy in unstable acral vitiligo., Materials and Methods: In this single-centre randomized prospective study, 60 patients aged 16-60 years having unstable acral vitiligo with symmetrical lesions were enrolled and randomized (1:1) into two groups. Patients in group A were instructed to apply topical tacrolimus 0.1% ointment on both vitiliginous and normal skin while patients in group B were instructed to apply topical tacrolimus 0.1% ointment only on vitiliginous skin for 6 months. Only the distal hand till the wrist joint was chosen for observation. Vitiliginous patches were assessed monthly for 6 months for a change in the number of lesions and total area involved, extension of preexisting lesions and adverse effects if any., Results: A reduction in the number of lesions was observed in both groups. The decrease in the number of lesions in group A was 5.6% as compared to 2.3% in group B (p-0.001). The decrease in depigmented area in group A was 10.5% as compared to 4.6% in group B (p-0.048). Treatment failure was seen in 11 out of 60 (18.3%) patients., Conclusion: Tacrolimus 0.1% ointment application showed effectiveness in preventing the appearance of new lesions in unstable acral vitiligo and hastening the repigmentation when applied on both lesional and perilesional skin in vitiligo., (© 2023 European Academy of Dermatology and Venereology.)

Catecholamines (epinephrine, norepinephrine and dopamine) are considered toxic to the melanocytes and may play an important role in the development of depigmented patches on the skin. This study was done to evaluate the levels of catecholamines in skin and plasma samples of active vitiligo patients' and gene expression changes in catecholamines' metabolism regulatory genes (COMT and GTPCH1), immunoregulatory genes (CTLA4 and PTPN22), and Catalase in active vitiligo patients. In this single-centre, prospective, case-control study, 30 patients with active vitiligo were recruited and skin biopsies from the perilesional site and plasma samples were collected. Skin biopsies from the normal site in vitiligo patients and healthy controls (n = 15) and plasma samples from controls were also obtained. Catecholamines' estimation was done via high-performance liquid chromatography. Gene expression variations were investigated via reverse transcription-polymerase chain reaction (PCR) and real-time PCR. Epinephrine, norepinephrine and dopamine levels were significantly higher in perilesional skin biopsies as compared to controls (P = 0.035, 0.024, and 0.006, respectively). However, epinephrine, norepinephrine and dopamine levels observed in patients' plasma samples were comparable to controls. The mRNA expression level of the Catalase gene was found to be upregulated at the perilesional site of patients as compared to the non-affected site of same patients (P < 0.001) and healthy controls (P = 0.037). Transcriptional expression of GTPCH1 and COMT were observed to be increased significantly at the perilesional site of patients in comparison to controls (P = 0.004 and P = 0.046, respectively). Our results support the presence of oxidative stress, inflammation and induced immune response in vitiligo patients at the perilesional sites. The increased inflammatory response may lead to catecholamines upregulation resulting in oxidative stress and melanocyte damage., (© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)

Background: Catecholamines (epinephrine, norepinephrine, and dopamine) have been proposed as a possible cause of melanocyte loss. Dopamine has been observed to cause apoptosis in melanocytes via reactive oxygen species development, but the effect on melanocyte adhesion and proliferation still remains to be elucidated. Thus, we explored the dose- and time-dependent toxicity of catecholamines and the effect of dopamine on the proliferation and adhesion potential of melanocytes., Materials and Methods: Primary culture of melanocytes was investigated in vitro for toxic effects of epinephrine, norepinephrine, and dopamine on metabolic activity via MTT [3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide) assay. Cells were observed microscopically for any phenotypic changes. Further cell proliferation, cell adhesion, and cell death pathway were explored under dopamine toxicity in dose- and time-dependent manner with RNase/PI method of cell cycle analysis, cell adhesion assay, and Annexin V-FITC/PI assay, respectively. Altered gene expressions were confirmed with a real-time polymerase chain reaction., Results: Metabolic activity of cells varied with time and different doses of epinephrine, norepinephrine, and dopamine. Dopamine was observed to be more toxic than epinephrine and norepinephrine. Melanocytes were observed to follow different cell death pathways at comparatively lower and higher concentrations of dopamine. Persistent exposure to dopamine resulted in decreased cell proliferation and adhesion potential with apoptotic changes. Gene expression changes also confirmed the weak adhesion and survival potential of cells under the toxic effects of dopamine., Conclusion: Dopamine can alter melanocytes' adhesion and survival potential, leading to apoptotic cell death or melanocytorrhagic loss., (© 2022 the International Society of Dermatology.)

Background: Mixed vitiligo (MV) is the coexistence of segmental vitiligo (SV) and non-segmental vitiligo (NSV). The literature on MV is sparse., Objective: To assess the clinicodemographic and treatment parameters in MV and compare them with SV., Methods: Clinical data of MV and SV patients enrolled in our pigmentary clinic from July 2015 to December 2019 were reviewed retrospectively and compared., Results: Out of a total of 4,371 vitiligo patients, 293 (6.7%) were SV while 74 (1.69%) were MV. As compared to SV, MV had significantly lower mean age of onset of segmental component (SC) (13.33 ± 9.01 vs. 15.70 ± 8.60 years, P = 0.03) and significantly higher proportion of patients with more than 1% body surface involvement by SC (66.2% vs. 51.5%, P = 0.03) and presence of leukotrichia in the SC (66.2% vs. 51.5%, P = 0.03). Topical agents and systemic immunosuppressive agents were significantly more effective in non-segmental component (NSC) as compared to SC of MV. Surgical modalities were the only effective treatment modality for SC., Limitations: Retrospective design, heterogeneity of treatment regimens., Conclusion: Early age of onset, larger (>1%) body surface area involvement, and leukotrichia in SV predict its progression into MV with time. Treatment response to different modalities varies significantly between SC and NSC of MV., (© 2022 the International Society of Dermatology.)

This is an exciting phase of vitiligo research with the current understanding of vitiligo pathogenesis and its translation to successful treatment. The pathogenetic origin of vitiligo revolves around autoimmunity with supporting role from many other factors like oxidative stress, inherent melanocyte defects, or defective keratinocytes and fibroblasts. Vitiligo can be classified into segmental or non-segmental depending upon the clinical presentation, or it can be classified as progressing or stable based on the activity of the disease. Vitiligo treatments need to be stratified depending upon which type of vitiligo we are treating and at which phase the vitiligo patient presents to us. There are two different aims of treatment of vitiligo. The first involves rescuing the melanocytes from the damage to arrest the depigmentation. The second strategy focuses on replenishing the melanocytes so that successful repigmentation is achieved. It is also important to maintain the disease in a stable phase or prevent relapse. As stability in non-segmental vitiligo is a dynamic process, maintenance of the stability of repigmentation is also an important consideration in the management of vitiligo. In this review, we shall briefly discuss the current options and future insight into the management of vitiligo., (© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

Noncultured epidermal cell suspension (NCES) is a well-established surgical treatment modality for stable vitiligo. The outcome of this procedure significantly depends on the method of recipient site preparation, a critical step to achieve cosmetically acceptable repigmentation. To compare the efficacy of recipient site preparation using three methods namely, dermabrasion, cryoblister, and dermaroller followed by NCES in stable vitiligo. In this single-center, prospective, intra-patient, randomized clinical trial; 36 participants having at least three vitiligo patches in same anatomic region with minimum lesional stability of 1 year were randomized 1:1:1 for recipient site preparation using manual dermabrasion, cryoblister, and dermaroller followed by NCES. Patients were followed up at 4, 8, and 12 weeks and assessment of extent and pattern of repigmentation, color match and patient satisfaction were done. Among 36 patients, 22 (61.1%) were females; mean (SD) age was 28.33 (9.4) years. Dermabrasion and cryoblister techniques showed equal efficacy with respect to extent of repigmentation (>75% repigmentation; 55.6% vs 47.2%; P = .63) and patient satisfaction score (20.2 ± 9.6 vs 19.9 ± 7.9, P = .194). However, dermabrasion was superior to cryoblister in terms of rapidity (65% vs 32.5% at 4 weeks, P = .04) and color match (47.2% vs 19.4%, P = .004). Dermaroller had poor repigmentation outcomes compared to both dermabrasion and cryoblister. Cryoblister as a method of recipient site preparation is equally effective as manual dermabrasion in NCES for attaining good to excellent repigmentation, but with risk of hyperpigmentation. However, dermaroller is inferior to both dermabrasion and cryoblister., (© 2020 Wiley Periodicals LLC.)

Background: Despite advances in surgical management of vitiligo, lesions on acral areas and bony prominences remain treatment refractory. There is lack of literature on the treatment efficacy of various surgical modalities over these treatment refractory sites., Objective: To compare the efficacy of three common methods of grafting in vitiligo in known resistant areas., Methods: A single-center interventional clinical trial involving 30 patients of stable vitiligo (disease stability ≥1 year) located over bony prominences and acral areas. All patients were treated with noncultured epidermal cell suspension (NCES), suction blister epidermal grafting (SBEG), and mini punch grafting (MPG) on three separate patches. Extent of repigmentation was assessed at 12 and 24 weeks, color matching and patient satisfaction were evaluated at 24 weeks., Results: Among 30 participants, 22 (73%) were females, mean age was 27.4 (±10.7) years, and the majority (93.3%) had nonsegmental vitiligo. At 12 weeks, repigmentation >75% was noted in 56.6, 60, and 16.6% of patches treated by NCES, SBEG, and MPG, respectively. At 24 weeks, results remained the same in both the NCES and SBEG groups, while the number of patches with >75% repigmentation increased to 23.3% in the MPG group. The difference in repigmentation rate between NCES and MPG as well as between SBEG and MPG achieved statistical significance. Color matching of treated area and patient satisfaction were better in NCES and SBEG groups compared to MPG., Conclusion: NCES and SBEG are superior to MPG with reasonably good efficacy and can be offered as a therapeutic modality for stable vitiligo patches over these sites., (© 2020 the International Society of Dermatology.)

Importance: Surgical interventions, notably noncultured epidermal suspension (NCES), are the next line of treatment in patients with vitiligo who fail to respond to medical therapy. Noncultured epidermal suspension is usually performed in patients with vitiligo with duration of clinical stability (DS) of 12 months or longer because DS is a vital parameter in determining outcome of NCES. In this pilot study, we planned to assess the efficacy of a novel combination of noncultured epidermal cell suspension and noncultured dermal cell suspension (NCES and NDCS) in patients with vitiligo with shorter DS (3-6 months)., Objective: To compare the efficacy of transplantation of NCES and NDCS vs NCES alone in patients with vitiligo with DS of 3 to 6 months., Design, Setting, and Participants: A single-center randomized clinical trial including 40 patients with focal, segmental, or generalized vitiligo with DS of 3 to 6 months or more than 12 months was carried out. Based on DS, 2 groups including 20 patients each were recruited (DS in group 1, 3 to 6 months; DS in group 2, more than 12 months). Each group was further randomized into 2 subgroups, A and B., Intervention: Patients in subgroups 1A and 2A underwent NCES alone, whereas patients in subgroups 1B and 2B underwent NCES and NDCS., Main Outcomes and Measures: Extent of repigmentation, color match, and pattern of repigmentation at 24 weeks., Results: Of the 40 study participants, mean (SD) age was 24.9 (4.0) years and 24 (60%) were women; in group 1 with DS for 3 to 6 months, more than 75% repigmentation at 24 weeks was observed in all 10 patients in subgroup 1B (NCES and NDCS) compared with 3 of 10 patients in subgroup 1A (NCES) (100% vs 30%, P = .003). In group 2 (DS > 12 months), the same was observed in 6 of 10 patients in subgroup 2A and 7 of 10 patients in subgroup 2B (NCES) (60% vs 70%, P > .99). The 2 groups and subgroups did not show any significant differences with respect to color matching and pattern of repigmentation., Conclusions and Relevance: Combination of NCES and NDCS resulted in excellent response in patients with vitiligo with shorter duration of clinical stability compared with NCES alone. This combination may be used early in the course of stable vitiligo without waiting for a period of 12 months or more since last clinical activity., Trial Registration: ClinicalTrials.gov identifier: NCT03013049.